Genomics & Genetics Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genomics & Genetics Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Gene Therapy
Apoptosis is induced in human prostate cancer cells by antisense targeting
July 14th, 2006
In a recent study, researchers from Canada reported on the induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide (ASO) targeting Bcl-2 and Bcl-xL genes. K. Yamanaka and colleagues, University British Columbia, wrote that the study was done "to determine whether a specifically designed bispecific (Bcl-2/Bcl-xL) antisense oligonucleotide (ASO) induces apoptosis and enhances chemosensitivity in human prostate cancer LNCaP cells, as Bcl-2 and Bcl-xL are both anti-apoptotic genes associated with treatment resistance and tumor progression in many malignancies, including prostate...
Source: Genomics & Genetics Weekly (2006-07-14)
|
